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Annexin A5 has been used for the detection of apoptotic cells, due to its ability to bind to phosphatidylserine (PS). Four diﬀerent
labeled Annexin A5 adducts were evaluated in rhesus monkey, with radiolabeling achieved via 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA). Of these adducts diﬀering conjugation methods were employed which resulted in nonspeciﬁc
radiolabeling (AxA5-I), or site-speciﬁc radiolabeling (AxA5-II). A nonbinding variant of Annexin A5 was also evaluated (AxA5-
IINBV), conjugation here was site speciﬁc. The fourth adduct examined had both speciﬁc and nonspeciﬁc conjugation techniques
employed (AxA5-IImDOTA). Blood clearance for each adduct was comparable, while appreciable uptake was observed in kidney,
liver, and spleen. Signiﬁcant diﬀerences in uptake of AxA5-I and AxA5-II were observed, as well as between AxA5-II and AxA5-
IINBV.N od iﬀerence between AxA5-II andAxA5-IImDOTA wasobserved, suggestingthat conjugatingDOTA nonspeciﬁcallydid not
aﬀect the in vivo biodistribution of Annexin A5.
1.Introduction
Apoptotic cells undergo a structural change in which phos-
phatidylserine (PS), a phospholipid normally present on the
inner leaﬂet of the cell membrane, becomes externalized and
available to bind the highly PS selective protein Annexin A5
[1]. The externalization of PS occurs early in the apoptosis
process, therefore Annexin A5 can be used to identify apop-
totic cells earlier than other methods [2]. As a consequence
many studies have been published on the use of Annexin A5
in noninvasive imaging for the in vivo detection of apoptosis
utilizing radionuclides such as
99mTc, 18F, and 124I[ 3–5].
Most of the work to date has focused on labeling Annexin-
Vw i t h
99mTc, with hydrazinonicotinamide (HYNIC) being
the most commonbifunctionalchelator (BFC)used totether
99mTc to Annexin A5 [6, 7].
99mTc-labeled Annexin A5 has
also been used clinically to monitor increases in apoptosis in
tumors after treatment [8, 9]. However it should be noted
that in tumors, Annexin A5 has been shown to detect not
only cells undergoing apoptosis but also necrosis as well as
other forms of cell death mechanisms [10, 11].
For protein radiolabeling, BFCs such as HYNIC are
typically conjugated to free amines such as lysine residues.
In the case of Annexin A5, the presence of multiple lysine
residues makes placement of a BFC at a speciﬁc location
impossible. In theory all of the lysine residues in Annexin
A5 could have a BFC attached, however in practice this is
not the case as the overall number of BFCs can be controlled
by adjusting the stoichiometry of the conjugation reaction.
This is important as overconjugation of BFCs can have a
detrimental eﬀect on ligand binding [12–14]. Previously, in
an attempt to facilitate a more reproducible and selective
conjugation of Annexin A5, a single cysteine residue was
incorporated using site-speciﬁc mutagenesis allowing for
site-speciﬁc conjugation [6]. This additional cysteine residue
was attached at the N-terminus, which is well removed
from the PS binding region and therefore should have no
detrimental eﬀect on PS-Annexin A5 binding [15].2 International Journal of Molecular Imaging
The ability of this N-terminally modiﬁed Annexin A5
to detect PS in vivo has been established in animal models
in which apoptosis was chemically induced. In one study,
both wild-type and N-terminally modiﬁed Annexin A5
adducts were compared in mice in which hepatic apoptosis
was induced by the anti-Fas monoclonal antibody (anti-Fas
mAb) [6].
99mTc was used to radiolabel both Annexin A5
adducts, with both adducts showing comparable increases in
liver uptake in mice pretreated with the anti-Fas mAb uptake
as compared to control animals. TUNEL staining conﬁrmed
increased level of apoptosis in liver after anti-Fas mAb treat-
ment. In a separate study [16], cycloheximide treatment in
rats resulted in elevated uptake of
99mTc labeled N-terminal
modiﬁed Annexin A5 in liver and spleen over controls. As
in the previous study, TUNEL staining conﬁrmed increased
level of apoptosis in liver after cycloheximide treatment.
These results demonstrate that the introduction of a cysteine
residuetowild-typeAnnexin A5doesnotinhibititsabilityto
bind to PS and that N-terminally modiﬁed Annexin A5 has
potential for the in vivo detection of apoptotic cells.
In this report we describe in vivo PET imaging studies
carried out with four diﬀerent Annexin A5 adducts in
rhesus monkeys. These adducts were radiolabeled with the
positron emitting isotope 64Cu (t1/2 = 12.7h,β+ = 17.6%,
Eavg = 278keV) via theBFC1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA). DOTA is one of the most
commonly used BFCs used to label biomolecules with 64Cu,
with imaging experiments being conducted up to 3 days
after administration of the radiolabeled biomolecule [17].
In this study, DOTA was conjugated to multiple free amine
sites present in wild-type Annexin A5 (AxA5-I)o rt ot h e
single cysteine residue present on the N-terminally modiﬁed
AnnexinA5(AxA5-II).Bothconjugationmethodsemployed
have signiﬁcant precedence and are well reported in the
literature. The primary goal of the study was to compare
the biodistribution of AxA5-II versus AxA5-I to see if there
were any factors that would preclude the clinical use of
AxA5-II. Rhesus monkeys were chosen as the test species,
as the pharmacokinetic (PK) parameters in nonhuman
primates are more closely related to human PK than
other preclinical species [18–20]. Additionally, a nonbinding
variant of Annexin A5 (AxA5-IINBV) was radiolabeled and
evaluated to provide insight into potential speciﬁc binding
of AxA5-II. AxA5-IINBV was similar to AxA5-II in that
a single cysteine residue incorporated at the N-terminus,
facilitating site-speciﬁc DOTA conjugation. The diﬀerence
between these Annexin A5 variants was that AxA5-IINBV
contained a single point mutation in each of the 4 domains
of Annexin A5 essential for calcium binding. This lack of
calcium binding precludes the ability of Annexin A5 to
bind to phosphatidylserine, with circular dichroism analysis
showing that these mutations did not signiﬁcantly alter the
folding of Annexin A5. Finally, to monitor the eﬀect the
conjugation method employed had on the biodistribution
and clearance of Annexin A5, a fourth Annexin A5 adduct
was evaluated, AxA5-IImDOTA.F o rAxA5-IImDOTA the N-
terminal functionalized Annexin A5 had DOTA conjugated
both non-speciﬁcally and on the terminal cysteine. A
schematic representation showing the diﬀering conjugation
methods employed to tether DOTA to Annexin A5 is shown
in Figure 1.
2.Materialsand Methods
2.1. General. All chemicals, unless otherwise stated, were
purchased from Sigma-Aldrich Chemical Co. (St. Louis,
MO). Water was distilled and then deionized (18MΩ/cm2)
by passing through a Milli-Q water ﬁltration system (Mil-
lipore Corp., Milford, MA). 64Cu was purchased from
either Washington University School of Medicine (St. Louis,
Missouri) or MDS Nordion (Ottawa, Canada). Wild-type,
N-terminal cysteine functionalized and N-terminal cysteine
functionalized scrambled Annexin A5 were obtained from
MosaMedix BV, The Netherlands. 1,4,7,10-tetraazacyclod-
odecane-1,4,7,10-tetraacetic acid mono(N-hydroxysuccin-
imidyl ester) and 1,4,7,10-Tetraazacyclododecane-1,4,7-tris-
acetic acid-10 maleimidoethylacetamide were obtained from
Macrocyclics (Dallas, TX).
2.2. Chemistry
2.2.1. DOTA Conjugation of Annexin A5 Analogs
AxA5-I. Wild-type Annexin A5 (1mg, 27.8nmol) and 1,4,
7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mon-
o(N-hydroxysuccinimidyl ester) (0.23mg, 0.28μM) were
stirred togetherfor18hrat4◦CinN a 2HPO4 (0.1M,pH8.5).
The reaction mixture was transferred to a Centricon YM-
10 Centrifugal Filter (Millipore Corp., Milford, MA) where
ammonium citrate (1.5mL, 0.1M, pH 5.5) was added and
then centrifuged for 20min. The supernatant was discarded
and an additional aliquot of ammonium citrate (4mL)
was added. It was again centrifuged for 20min and the
supernatant was discarded. This process was repeated 3
times. Puriﬁed AxA5-I was collected in ammonium citrate
(200μL), the concentration determined by UV absorbance
and the AxA5-I solution, was stored for up to 5 months at
4◦C.
AxA5-II and AxA5-IINBV. Either N-terminal cysteine-
modiﬁed Annexin A5 or the N-terminal cysteine-modiﬁed
scrambled Annexin A5 variant (3.6mg, 50nmol) was
dissolved in HEPES buﬀer (500μL, 25mM, pH 7.2).
Dithiothreitol (1.57mg, 10.2nmol) was added and the
resulting solution diluted to 1mL with HEPES buﬀer. The
reaction mixture was incubated at 37◦Cf o r6 0m i n u t e s
and transferred to a Centricon YM-10 Centrifugal Filter
where an additional aliquot of HEPES buﬀer was added
(3.0mL). The resulting solution was centrifuged for 20min,
and the supernatant discarded. Additional HEPES buﬀer
(4mL) was added and the centrifugation process repeated.
The reduced Annexin A5 was collected in HEPES buﬀer
(200μL) and 1,4,7,10-tetraazacyclododecane-1,4,7-tris-
acetic acid-10 maleimidoethylacetamide (0.1mg, 100nmol)
was added. The solution was diluted to 1mL by the addition
of HEPES buﬀer. The resulting reaction mixture was
incubated at 37◦C with gentle mixing for 18h. The reactionInternational Journal of Molecular Imaging 3
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Figure1:Schematicrepresentationshowingconjugationmethodsemployedtotether DOTA non-speciﬁcallytomultiple(n>1)freeamines
present in Annexin A5 (AxA5-I)orsite speciﬁcally to the singlecysteine residue present onthe N-terminally modiﬁedAnnexin A5(AxA5-II
and AxA5-IINBV). For AxA5-IImDOTA both conjugation methods were employed.
mixture was transferred to a Centricon YM-10 Centrifugal
Filter where ammonium citrate (3.0mL, 0.1M, pH 5.5)
was added. After centrifugation for 20min, the supernatant
was discarded, and an additional aliquot of ammonium
citrate (4mL) was added. It was again centrifuged for 20min
and the supernatant discarded. This process was repeated
three times. Puriﬁed AxA5-II or AxA5-IINBV were collected
in ammonium citrate (200μL), the concentrations were
determined byUVabsorbance, and the solutionswere stored
for up to 5 months at 4◦C.
AxA5-IImDOTA. DOTA was conjugated to the single cysteine
residue present on the N-terminal cysteine functionalized
Annexin A5 via 1,4,7,10-tetraazacyclododecane-1,4,7-tris-
aceticacid-10maleimidoethylacetamide using identicalreac-
tion conditions to those described for AxA5-II and AxA5-
IINBV. After initial puriﬁcation, DOTA was conjugated in a
nonsite-speciﬁc fashion using 1,4,7,10-tetraazacyclododec-
ane-1,4,7,10-tetraacetic acid mono(N-hydroxysuccinimidyl
ester) in conditions identical to those described for AxA5-
I. After ﬁnal puriﬁcation, AxA5-IImDOTA was collected in
ammonium citrate (200μL), the concentration determined
by UV absorbance and the AxA5-IImDOTA solutionstored for
up to 5 months at 4◦C.
2.3. Radiochemistry. 64Cu radiolabeling experiments with all
DOTA functionalized Annexin A5 adducts were performed
in an identical fashion as follows: to the DOTA-conjugated
Annexin A5 adduct was added 64CuCl2 in 0.1M HCl and
the mixture diluted with ammonium citrate (0.1M, pH 5.5)
to a volume of 100μL. The reaction mixture was incubated
at 37◦C for 30min, allowed to cool for 5min before
diethylenetriaminepentaacetic acid (DTPA, 3μL, 10mM)
was added. The 64Cu-labeled Annexin A5 was puriﬁed via
a Bio-Spin 30 column (Bio-Rad, Hercules CA) that had
been pretreated with 3 × 1mL of phosphate buﬀered saline
(PBS). Radiochemical purity was determined by injection
on an analytical Waters 2795 HPLC system (Milford, MA)4 International Journal of Molecular Imaging
equipped with a Waters 996 UV detector and β-RAM Model
4 Radio-HPLC detector (IN/US Systems, Brandon FL) using
a TSKgel G3000SWXL size exclusion column and PBS as the
mobile phase. All 64Cu labeled Annexin A5 adducts eluted
witharetentiontime of8.9min. This retentiontimematches
that observed for all nonradiolabeled Annexin A5 adducts as
well as wild-type Annexin A5.
2.4. Red Blood Cell Calcium Titration Assay. The relative
binding of 64Cu-labeled AxA5-I, AxA5-II or AxA5-IINBV to
phosphatidylserine was determined by binding to RBC at
various Ca2+ concentrations [21]. A ﬁxed concentration of
64Cu-labeled AxA5-I, AxA5-II or AxA5-IINBV along with a
ﬁxed number of preserved red blood cells (Beckman Coulter
“4C ES normal” Hialeah, FL) was titrated against increasing
concentrations of CaCl2 (0–6mM), with each concentration
tested in duplicate. After incubation for 8min at room
temperature, the cells were pelleted from the media by
centrifugation and the supernatant was removed. The pellets
were then resuspended in assay buﬀer containing CaCl2 at
the same concentrations as the original incubation buﬀer,
centrifugedasecondtimeandthesupernatantwasdiscarded.
The level of 64Cu-labeled Annexin A5 bound to each red
blood cell pellet was determined by measuring the counts
per minute (CPM) using a gamma counter (1480 Wizard 3
  ,
PerkinElmer, Waltham MA).
2.5. PET Imaging Studies. PET studies were conducted in
healthy adult male rhesus monkeys (n = 3, weight
9.27±0.57kg), with the same 3 animals used for each
annexin adduct. All procedures were conducted in accor-
dance with the guidelines of the Institutional Animal Care
and Use Committee of Merck (West Point, PA) and guide-
lines for the care and use of mammals in neuroscience and
behavioral research (National Research Council 2003). Ani-
mals were housed in temperature- and humidity-controlled
rooms in fully AAALAC (Association for Assessment and
Accreditation of Laboratory Animal Care) accredited facili-
ties and fed a commercially prepared high protein monkey
diet (Lab Diet no. 5045, PMI Nutrition International Inc.,
Brentwood, MO); water was oﬀered ad libitum. Fresh fruits
and vegetables were provided daily and animal housing
rooms were maintained on a twelve hour light/dark cycle.
AnimalswereinitiallysedatedwithKetamineHydrochlo-
ride (10mg/kgIM) anesthesia and maintained with IV Pro-
pofol anesthesia (5mg/kg for induction and 0.4mg/kg/min
throughout the scanning procedure). Following the ini-
tial induction with Propofol, the animal was intubat-
ed and ventilated with medical grade compressed air at
∼10cc/breath/kg and 20 respirations per minute. Monkeys
were instrumented with a temperature probe, a pulse
oximeter and an end tidal CO2 monitor. End tidal CO2
was maintained at 40±2mmHg, with body temperature
maintained between 98.5–100◦F using K-module heating
pads (Harvard Apparatus, Holliston, MA).
Following IV administration of the radiotracer a whole
body dynamic scan (180min) was performed encompassing
ﬁveﬁeldsofview(24staticframes). 24haftertracerinjection
a single whole body image was acquired. The initial AxA5-
II 3h dynamic scan was acquired using a Siemens HR+ PET
scanner(SiemensMedicalSolution,HoﬀmanEstates,IL).All
subsequent PET scans were performed using a GE Discovery
STPET/CT(GE Healthcare, Waukesha, WI, USA).BothPET
scanners were cross-calibrated with the dose calibrator using
an 18F cylinder according to the manufacturer’s standard
operating procedures.
For whole body images acquired using the GE PET/CT,
each image consisted of 5bed positions covering 72.9cm
axially (voxel size: 2.4mm×2.4mm×3.3mm). Images were
acquired in 2D mode with random correction from sin-
gles and reconstructed with Ordered-Subsets Expectation-
Maximization (OS-EM) using 2 iterations and 30 subsets.
CT-based attenuation and scatter correction was carried out
as implemented by the camera manufacturer. A Gaussian
ﬁlter (FWHM = 3mm) was applied to the reconstructed
PET image. Before the PET acquisitions, a noncontrast
CT (60mA, 120kVp) was acquired for PET attenuation
correction. After completion of the whole body scan, a
contrast CT (200mA, 120kVp) using 2.5mL/kg Omnipaque
300 was performed to assist with organ identiﬁcation.
Whole body images acquired with the Siemens HR+
PET scanner consisted of 5 bed positions covering 69.4cm
axially (voxel size: 2.6mm×2.6mm×2.6mm). Images were
acquired in 2D mode and reconstructed using ﬁltered back-
projection with scatter and 68Ge 10min/bed transmission-
based attenuation correction as implemented by the camera
manufacturer.
For the 3h dynamic scan, regions of interest were drawn
for the entire left kidney and liver using the summed PET
image, while a 5mm radius sphere was placed inside the left
ventricle of the heart using the initial PET image. For the
24h scans, regions of interest were drawn for left kidney,
liver, and spleen using the PET image. All regions were decay
corrected to time of injection and expressed as standardized
uptake values (SUV) which was calculated for each region of
interest at time point t as the ratio of decay-corrected tissue
radioactivity concentration (MBq/mL) at time t, c(t), and
injected dose (MBq) at the time of injection (t = 0) divided
by body weight (g).
2.6.Statistical Methods. Sigma-Statv3.1was usedfor statisti-
cal testing.One-way analysis of variance (ANOVA)tests were
used to compare results among groups, with all after hoc
pairwise comparisons done using the Fisher LSD method.
Statisticalsigniﬁcance was set at P<. 05.Forgroupsin which
nostatisticaldiﬀerenceswereobserved,thestatisticalanalysis
should be treated with caution due to the low number of
animals (n = 3) used.
3.Results
3.1. Radiolabeling. The DOTA conjugated Annexin A5
adducts were labeled by incubating them with 64Cu at 37◦C
for 30min. Upon puriﬁcation by a Bio-Spin 30 column, the
64Cu-labeled Annexin A5 adducts were obtained with high
radiochemical purity and speciﬁc activity (Table 1).International Journal of Molecular Imaging 5
Table 1: Radiochemical purity and speciﬁc activity of annexin A5 adducts, Mean±SD (n = 3).
AxA5-I AxA5-II AxA5-IINBV AxA5-IImDOTA
% Radiochemical Purity 98.2±3.2 96.5±3.6 98.9±0.1 96.0±4.4
Speciﬁc activity (GBq/μmol) 43.0±14.7 27.2±15.7 24.1±2.3 16.4±20.5
Activity injected (MBq) 88.8±33.3 99.9±7.4 81.4±22.2 48.1±40.7
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Figure 2: Binding results of 64Cu-labeled AxA5-I, AxA5-II,a n d
AxA5-IINBV to preserved RBCs with exposed phosphatidylserine at
increasing Ca2+ concentrations. Measurements were performed in
duplicate for each Ca2+ concentration.
3.2. Red Blood Cell Calcium Titration Assay. The RBC titra-
tion binding assay showed that 64Cu-labeled AxA5-I, AxA5-
II and AxA5-IINBV had negligible binding to RBCs in the
absence of Ca2+.F o rb o t hAxA5-I and AxA5-II,t h e r e
was a corresponding increase in RBC binding as the Ca2+
concentration increased, with maximum binding reached
seen at a Ca2+ concentration above 3mM. For AxA5-IINBV
no binding to the RBCs was observed regardless of the Ca2+
concentration (Figure 2).
3.3. PET Imaging Studies. For each 64Cu-labeled Annexin
A5 adduct, two PET scanning sessions were conducted and
the results are shown in Figure 3. Summed whole body PET
images of each adduct at 24h in the sagittal plane are shown
in Figure 4.
The ﬁrst, a 3h dynamic scan, began immediately follow-
ing administration of the radiotracer. Clearance from the
blood of all four adducts was comparable as judged by the
SUV levels in the left ventricle, with levels <1 SUV seen for
all fouradductsby 3h. Each adductbehavedsimilarly during
this initial dynamic scan, with highest uptake in kidney
followed by liver. AxA5-I had the highest kidney SUV value;
88.1±4.3 at 3h, which was signiﬁcantly higher than both
AxA5-II (P = .01) and AxA5-IImDOTA (P = .04).
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Figure 3: SUVs as determined by drawing regions of interest
around target tissue and expressed as Mean±SD (n = 3) of target
organs at end of 3h dynamic scan and/or 24hr after injection of
64Cu-labeled Annexin A5 adducts. ∗P<. 05 versus 3h AxA5-I
Kidney, ∗∗P<. 05 versus 3h AxA5-I Liver, †P<. 01 versus 24h
AxA5-ILiver, ‡P<. 05versus24hAxA5-IINBV Liver, #P<. 01versus
24h AxA5-I and AxA5-IINBV Spleen.
For each Annexin A5 adduct a second PET imaging
session was performed 24h after radiotracer administration.
As was the case at 3h, the kidney was still the organ of
highest uptake for all adducts. However, at 24h only AxA5-
I showed a signiﬁcant drop in kidney uptake compared to
3h, 88.1±4.3 versus 54.1±4.5 (P = .003). In terms of
liver uptake, each adduct showed no signiﬁcant reduction
at 24h as compared to 3h. Similar to what was seen at
3h, at 24h liver uptake of both AxA5-II and AxA5-IImDOTA
was signiﬁcantly higher than AxA5-I; P = .001 and .009
respectively. Additional, by 24h, liver uptake of AxA5-II was
signiﬁcantly higher than AxA5-IINBV (P = .04).
At the 24h time point the spleen could also be readily
identiﬁed. During the initial 3h dynamic scan a region of
interest for the spleen could not be drawn accurately as there
was poor delineation between it and the left kidney. Spleen
SUV uptake of AxA5-II was signiﬁcantly higher than both
AxA5-I (P = .008) and AxA5-IINBV (P = .008). Similar to
AxA5-II, spleen uptake AxA5-IImDOTA was also signiﬁcantly
higher than both AxA5-I (P = .009) and AxA5-IINBV (P =
.01).6 International Journal of Molecular Imaging
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Figure 4: Summed whole body PET images from 24h of 64Cu labeled AxA5-I, AxA5-II, AxA5-IINBV,a n dAxA5-IImDOTA showing liver
(crosshairs) and right kidney. PET images obtained with the same rhesus monkey and are shown along with a whole body contrast CT scan
obtained after the AxA5-I scan.
4.Discussion
The primary goal of this study was compare the biodistri-
bution of wild-type Annexin A5 radiolabeled in a nonsite-
speciﬁc fashion (AxA5-I)to an Annexin A5 analog amenable
to site-speciﬁc radiolabeling by the incorporation of a single
cysteine residue at the N-terminus (AxA5-II). This was done
to see if any signiﬁcant diﬀerences in the in vivo distribution
of AxA5-I and AxA5-II existed, and if these diﬀerences
would preclude the clinical use of AxA5-II. In addition,
two other Annexin A5 analogues were examined: AxA5-
IINBV and AxA5-IImDOTA. AxA5-IINBV was radiolabeled in
an identical fashion as AxA5-II;h o w e v e rt h ea m i n oa c i d
sequence had been scrambled to remove PS aﬃnity. AxA5-
IINBV was evaluated to see if any AxA5-II uptake could be
attributed to speciﬁc PS binding. For AxA5-IImDOTA,b o t h
DOTA conjugation methods were employed to discover if
this had any eﬀect on the in vivo distribution of Annexin
A5. These adducts were evaluated in rhesus monkeys as
numerous studies have shown that the pharmacokinetic
parameters displayed in nonhuman primates is more predic-
tive ofhuman parameters than is achievable with othermore
commonly available laboratory species [18–20].
Before in vivo imaging work was undertaken, in vitro
studies based upon the previously reported red blood
cell (RBC) calcium titration assay were carried out [21].
Determination of Annexin A5 aﬃnity using this assay is
possible since the binding of Annexin A5 to PS is dependent
on the available Ca2+ concentration [22]. PS expression on
the cell surface of RBCs increases with age, therefore, in
the presence of Ca2+, Annexin A5 will bind to RBCs [23].
For a ﬁxed concentration of Annexin A5 and PS, which is
maintained by keeping the number of RBCs constant, there
should be a gradual increase in binding of Annexin A5 to
RBCsas the Ca2+ concentration is increased, with maximum
binding being achieved at some Ca2+ concentration. AxA5-
I and AxA5-II were examined to see if DOTA conjugation
aﬀected their ability to bind to PS, and AxA5-IINBV was
examined as a negative control since no binding would be
expected at any Ca2+ concentration with this variant. All
three Annexin A5 adducts showed very low binding to RBCs
in the absence of Ca2+.H o w e v e r ,a st h eC a 2+ concentration
increased, both AxA5-I and AxA5-II showed a gradual
increase in RBC binding with maximum binding at a Ca2+
concentration above 3 mM. As expected, for AxA5-IINBV no
change in RBC binding was observed regardless of the Ca2+
concentration.
For the in vivo imaging experiments, each 64Cu-labeled
Annexin A5 adduct was given as a bolus IV injection.
Although diﬀerences in speciﬁc activity between the various
Annexin A5 adducts were observed, the overall mass of any
Annexin A5 variant administered was between 2–8nmol. At
such low levels, variations in the amount of Annexin A5
administered should have no impact on either its clearance
or distribution. A 3h dynamic scan began immediately after
administration of the tracer and a second imaging session
was conducted 24h after radiotracer administration. The
data showed that while the in vivo distribution of the four
adducts in rhesus monkeys followed a similar pattern, some
signiﬁcant diﬀerences in organ uptake were observed. After
the initial bolus injection of the radiolabeled Annexin A5
adducts, all four adducts showed fast blood clearance as
determined by SUV levels in the left ventricle. In each case
during this initial 3h scan, both kidney and liver were
found to have moderate to high uptake of radioactivity,
with kidney being the organ of highest uptake for all four
adducts. This is not surprising since Annexin A5 at 36kDa is
lowerthanthe60kDarenalexcretionlimit[24].Compounds
with a molecular weight greater than 60kDa are excreted
primarily via the liver. This is also similar to previously
reported clinical studies with
99mTc radiolabeled Annexin
A5, where the kidney was the organ of highest uptake [25–
27]. For all 64Cu-labeled Annexin A5 adducts examined,
kidney uptake increased steadily after IV administration
before reaching their peak uptake by 60min, with levels
remaining unchanged by 3h. Kidney uptake of AxA5-I wasInternational Journal of Molecular Imaging 7
signiﬁcantly higher than both AxA5-II (P = .02) and AxA5-
IImDOTA (P = .036) at 3h. Additionally, AxA5-I showed a
statistically signiﬁcant reduction in kidney uptake by 24h
as compared to 3h (P = .003). No such reduction in
uptake at 24h was seen for AxA5-II, AxA5-IINBV,o rAxA5-
IImDOTA. An explanation for these diﬀerences is unknown at
present. However, it has been reported that kidney uptake
of Annexin A5 is predominately non-speciﬁc in nature
[28], and can be diminished through the incorporation of
various chelating moieties [29, 30]. It would therefore be a
reasonable assumption that the method used to conjugate
DOTA to Annexin A5 could have an eﬀect on kidney
uptake and clearance, as could the overall number of DOTA
conjugates present. This is an important question, as AxA5-
I has multiple DOTA moieties conjugated to free amines
in a nonspeciﬁc fashion, where AxA5-II has a single DOTA
conjugated to the N-terminal cysteine incorporated via site-
speciﬁc mutagenesis. AxA5-IImDOTA was investigated in an
attempt to address this question, as both DOTA conjugation
methods were applied: DOTA was conjugated both at the
N-terminal cysteine similar to AxA5-II, and non-speciﬁcally
to multiple free amines as with AxA5-I. Therefore, any
diﬀerences observed between AxA5-II and AxA5-IImDOTA
could be attributed to the additional DOTA moieties present
as a result of non-speciﬁc conjugation. When the SUV
data generated for AxA5-II and AxA5-IImDOTA was analyzed
however no diﬀerence in kidney uptake or clearance was
observed.ThisdatashowsthattheadditionalDOTAmoieties
present in AxA5-IImDOTA as compared to AxA5-II caused
no change in the clearance of Annexin A5 and cannot be
used to explain the diﬀerences seen between AxA5-I and
AxA5-II.T h e s ed i ﬀerences must therefore be a result of the
additional cysteine residue found in AxA5-II or in its DOTA
conjugation.
As previously mentioned, during the initial 3h dynamic
scan in addition to the kidney, the liver was the only other
organ with appreciable uptake in which accurate SUVs
could be generated. Similar to the kidney, by 3h there were
signiﬁcant diﬀerences in uptake between AxA5-I and AxA5-
II (P = .01), this was repeated at 24h (P = .001). In
addition to the kidney and liver, for all four adducts the
spleen was the only other organ which showed appreciable
uptake. However, due to high kidney spillover, accurate
measurement during the initial 3h dynamic scan was not
possible. Reliable data for the spleen could only be generated
at the 24h time point. As in the liver, uptake of AxA5-II in
the spleen was signiﬁcantly higher than AxA5-I (P = .005),
as was AxA5-IImDOTA (P = .009). Importantly, there were
no signiﬁcant diﬀerences in liver or spleen uptake between
AxA5-II and AxA5-IImDOTA. Thiscorrelatestowhat wasseen
with both these adducts in the kidney, in that the additional
DOTA moieties present in AxA5-IImDOTA caused no change
in the uptake or clearance of Annexin A5.
The diﬀerences in kidney, liver, and spleen uptake seen
between AxA5-I and AxA5-II are not without precedent.
In a previous reported study in which
99mTc radiolabeled
wild-type Annexin A5 and N-terminally cysteine modiﬁed
Annexin A5 were compared in NMRI mice, similar diﬀer-
ences in organ uptake were found [6]. The
99mTc-labeled
species in this study were similar to AxA5-I and AxA5-II,
the diﬀerence being the bifunctional chelator hydrazinoni-
cotinamide (HYNIC) was used to tether
99mTc to Annexin
A5. However, the chemistry employed for the HYNIC conju-
gation was similar to that used here for DOTA conjugation.
The cause of the discrepancy seen in the in vivo distribution
of AxA5-I and AxA5-II is as yet unknown. But from the
comparison between AxA5-II, which had DOTA conjugated
site speciﬁcally and AxA5-IImDOTA in which DOTA was
conjugated both site speciﬁcally and non-speciﬁcally in a
manner identical to the DOTA conjugation found in AxA5-
I, it is known that the additional DOTA moieties present as
a result of non-speciﬁc conditions did not cause these diﬀer-
ences. Rather, the source of the diﬀerences found between
AxA5-I and AxA5-II must be a result of the additional
cysteine present in AxA5-II or in its DOTA conjugation.
To see if any uptake of AxA5-II could be attributed to
PS binding, a nonbinding variant of AxA5-II (AxA5-IINBV)
was evaluated. AxA5-II and AxA5-IINBV diﬀered only in
that a single amino acid residue in each of the 4 domains of
Annexin A5 responsible for the binding of calcium had been
replaced. This deletion of calcium binding precludes the
ability of AxA5-IINBV to bind to PS, with circular dichroism
showing that these point mutations did not alter the folding
of AxA5-IINBV as compared to AxA5-II. Therefore, any
diﬀerences in their in vivo uptake could highlight potential
speciﬁc PS binding. Blood clearance of both AxA5-II and
AxA5-IINBV as well as kidney uptake at both 180min
and 24h was similar. However uptake of AxA5-II was
signiﬁcantly higherthanAxA5-IINBV in both liver(P = .039)
and spleen (P = .008) at 24h. This evidence suggests that
elevated uptake of AxA5-II as compared to AxA5-IINBV
in both organs could be driven by speciﬁc binding to
PS, however further work would be required to conﬁrm
this. Analogous ﬁndings though have also been reported
previously [28]. In this case, similar reductions in spleen
and liver uptake of Annexin A5 were caused by reducing its
PS aﬃnity by modifying one or more of the four binding
domains.
5.Conclusion
From in vitro analysis and consistent to what was previously
reported, incorporation of a cysteine residue into the N-
terminus of Annexin A5 and subsequent selective DOTA
conjugation did not impair PS binding as compared to
wild-type Annexin A5, in which DOTA was conjugated
in a nonspeciﬁc fashion. An in vivo evaluation in rhesus
monkeys showed that while signiﬁcant diﬀerences in the
biodistribution of AxA5-I versus AxA5-II were found, these
diﬀerences do not suggest any liability for the clinical use
of AxA5-II for the detection of apoptosis in vivo.H o w e v e r ,
the cause of the diﬀerences in uptake observed between
AxA5-I and AxA5-II is not clear, though it must be a
result of the additional cysteine present in AxA5-II or in
its DOTA conjugation. This assumption can be made as
when AxA5-II (speciﬁc DOTA conjugation) and AxA5-
IImDOTA (speciﬁc and non-speciﬁc DOTA conjugation) were8 International Journal of Molecular Imaging
compared, no signiﬁcant diﬀerences in their biodistribution
in rhesus monkey were found. This comparison indicates
that conjugating DOTA non-speciﬁcally did not cause the
diﬀerences in tissue uptake and clearance seen between
AxA5-I and AxA5-II. Finally, the higher uptake of AxA5-II
in the spleen and liver at 24h as compared to AxA5-IINBV
could suggest speciﬁc binding of AxA5-II to PS in these
organs, though further work would have to be undertaken
to conﬁrm this hypothesis.
Disclaimer
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